Search

Cynthia Arbeeny Phones & Addresses

  • 1 Morningside Dr, Shrewsbury, MA 01545 (508) 898-9795
  • Stow, MA
  • East Hanover, NJ
  • 17 Garfield Dr, Westborough, MA 01581 (508) 366-3314 (508) 898-9795
  • Mountain Lakes, NJ
  • 38 Orchard Dr, Stow, MA 01775 (508) 366-3314

Work

Position: Homemaker

Education

Degree: High school graduate or higher

Publications

Us Patents

Methods Of Treating Fatty Liver Disease

View page
US Patent:
20090105125, Apr 23, 2009
Filed:
May 9, 2007
Appl. No.:
12/227076
Inventors:
Hongmei Zhao - Northborough MA, US
Nelson S. Yew - West Upton MA, US
Seng H. Cheng - Natick MA, US
Canwen Jiang - Southborough MA, US
Cynthia Marie Arbeeny - Westborough MA, US
International Classification:
A61K 31/40
A61K 31/16
A61K 31/4025
A61K 38/28
A61K 31/357
US Classification:
514 4, 514613, 514452, 514408, 514422
Abstract:
The disclosure provides methods for treating fatty liver disease and associated conditions by inhibiting the synthesis of glucosphingolipids, as exemplified by the use of glucosylceramide synthase substrate analogs.

Methods Of Treating Fatty Liver Disease

View page
US Patent:
20170281593, Oct 5, 2017
Filed:
Dec 19, 2016
Appl. No.:
15/383602
Inventors:
- Cambrige MA, US
Nelson S. Yew - West Upton MA, US
Seng H. Cheng - Natick MA, US
Canwen Jiang - Southborough MA, US
Cynthia Marie Arbeeny - Marlborough MA, US
International Classification:
A61K 31/395
C07D 405/06
A61K 31/4025
A61K 31/4245
A61K 31/40
A61K 45/06
Abstract:
The disclosure provides methods for treating fatty liver disease and associated conditions by inhibiting the synthesis of glucosphingolipids, as exemplified by the use of glucosylceramide synthase substrate analogs.

Methods Of Treating Fatty Liver Disease

View page
US Patent:
20150051261, Feb 19, 2015
Filed:
Apr 8, 2014
Appl. No.:
14/247732
Inventors:
- Cambridge MA, US
Nelson S. Yew - West Upton MA, US
Seng H. Cheng - Natick MA, US
Canwen Jiang - Southborough MA, US
Cynthia Marie Arbeeny - Marlborough MA, US
Assignee:
Genzyme Corporation - Cambridge MA
International Classification:
C07D 405/06
A61K 45/06
A61K 31/4025
US Classification:
514422
Abstract:
The disclosure provides methods for treating fatty liver disease and associated conditions by inhibiting the synthesis of glucosphingolipids, as exemplified by the use of glucosylceramide synthase substrate analogs.
Cynthia M Arbeeny from Shrewsbury, MA, age ~73 Get Report